for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cyclerion Therapeutics Inc

CYCN.OQ

Latest Trade

3.97USD

Change

-0.18(-4.34%)

Volume

135,672

Today's Range

3.90

 - 

4.19

52 Week Range

2.09

 - 

8.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.15
Open
4.09
Volume
135,672
3M AVG Volume
24.60
Today's High
4.19
Today's Low
3.90
52 Week High
8.95
52 Week Low
2.09
Shares Out (MIL)
34.13
Market Cap (MIL)
135.51
Forward P/E
--
Dividend (Yield %)
--

Next Event

Cyclerion Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics For Praliciguat

Cyclerion Therapeutics Reports Full Year 2020 Financial Results And Corporate Update

Cyclerion Anticipates That Its Current Cash Will Be Sufficient To Fund Its Current CNS Priorities

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.

Industry

Biotechnology & Drugs

Contact Info

155 Federal Street, Suite 700

BOSTON, MA

02110-1727

United States

+1.617.6217722

https://www.cyclerion.com/

Executive Leadership

Marsha H. Fanucci

Independent Chairman of the Board

Peter M. Hecht

Chief Executive Officer, Director

Anjeza Gjino

Chief Financial Officer, Corporate Secretary

Cheryl Gault

Chief Operating Officer

Andreas Busch

Chief Scientific Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
100.83
Price To Book (MRQ)
2.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.25
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-65.99
Return on Equity (TTM)
-59.14

Latest News

Latest News

BRIEF-Cyclerion Therapeutics Says Closed Enrollment For Olinciguat Phase 2 Strong Scd Study For Sickle Cell Disease Topline Data Readout Expected Q3 2020

* CYCLERION THERAPEUTICS INC - CLOSED ENROLLMENT FOR OLINCIGUAT PHASE 2 STRONG SCD STUDY FOR SICKLE CELL DISEASE; TOPLINE DATA READOUT EXPECTED Q3 2020

MOVES-Activist hedge fund Sarissa hires president in push for growth

Sarissa Capital Management LP, the activist hedge fund run by Alexander Denner that invests in pharmaceutical and healthcare companies, has hired asset management veteran Eric Vincent as president, according to his LinkedIn profile and two people familiar with the matter.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up